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2 
Highlights 30 
･We examined the associations of central systolic aortic pressure and brachial 31 
systolic pressure with flow mediated dilatation in apparently healthy Japanese 32 
men. 33 
･Higher central aortic pressure rather than higher brachial blood pressure was 34 
associated with lower flow mediated dilatation; the association was evident for 35 
men without antihypertensive medication. 36 
･Our finding suggests that central systolic aortic pressure, rather than brachial  37 
systolic blood pressure, is a useful marker for endothelial dysfunction in men.  38 
 39 
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3 
Background and aims. Endothelial dysfunction is considered the first stage in 56 
the development of atherosclerosis and cardiovascular disease, and brachial flow-57 
mediated dilation (FMD) is a measure of endothelial function. It is uncertain 58 
which of central systolic aortic pressure (CAP) or brachial systolic blood 59 
pressure (SBP) is more strongly associated with FMD. Therefore, we examined 60 
the correlations of CAP and SBP with FMD in Japanese men. 61 
Methods. The study subjects comprised 507 male volunteers aged 30–79 years 62 
that were residents in two communities under the Circulatory Risk in 63 
Communities Study (CIRCS) between 2013 and 2015. The low percent change 64 
of FMD (%FMD) ≤5.0% after 5 minutes of reactive hyperemia evaluated by the 65 
brachial artery was used to assess endothelial dysfunction. Values of CAP and 66 
SBP were divided into tertiles, with the lowest tertile used as a reference.  67 
Results. After adjustment for cardiovascular risk factors, the multivariable odds 68 
ratio (95% CI) of low FMD for the highest versus the lowest tertile of CAP was 69 
1.5(0.9–2.6) for total subjects and 1.3(0.7–2.5) for those with and 2.4(1.2–4.8) 70 
for those without antihypertensive medication use. The corresponding odd ratios 71 
for the highest versus lowest tertile of SBP were 0.9(0.5–1.5), 0.8(0.3–2.2), and 72 
1.3(0.7–2.5). 73 
Conclusions. Higher CAP levels were associated with low FMD for men without 74 
antihypertensive medication, but such an association was not found for SBP 75 
levels. (word count: 227) 76 
Key words: Central aortic pressure ■ Endothelial function ■ Japanese men ■ 77 
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Cross sectional study 78 
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1. Introduction 100 
Cardiovascular diseases remain the major cause of morbidity and mortality in 101 
developed countries, with atherosclerosis being the leading underlying cause (1). 102 
Endothelial dysfunction is considered the first stage in the development of 103 
atherosclerosis and cardiovascular disease (2, 3). Endothelial cells form the inner 104 
lining of all blood vessels and play a central role in vascular homeostasis; they 105 
respond to stimuli, such as hemodynamic changes or blood-borne signals by 106 
releasing vasoactive substances (4). Brachial flow-mediated dilation (FMD) is a 107 
measure of the release of nitric oxide by the endothelium due to a transient flow 108 
stimulus (5) and low brachial FMD was regarded as a cardiovascular disease risk 109 
factor (4, 5). 110 
Hypertension is a recognized risk factor for the development of atherosclerosis 111 
and cardiovascular disease (6-8). Central systolic aortic pressure (CAP) has been 112 
reliably determined by mathematically transforming the radial artery pulse 113 
waveform to the aortic pulse waveform (9-10). Several studies have also reported 114 
that CAP levels were strongly associated with risk of mortality from 115 
cardiovascular disease (11, 12). The Circulatory Risk in Communities Study 116 
(CIRCS) of 3,002 Japanese men and women reported that CAP levels were 117 
correlated more strongly with cardiovascular risk factors than brachial systolic 118 
blood pressure (SBP) levels (13). However, evidence for the correlation of CAP 119 
with FMD is limited. Additionally, to date, it is unclear which of CAP or SBP is 120 
more strongly associated with flow-mediated dilatation. In this study, we 121 
6 
investigated the relationship of CAP and SBP with FMD in the general 122 
population. 123 
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2．Materials and Methods 144 
2.1. Subjects 145 
FMD and CAP measurements were conducted in two communities of the CIRCS, 146 
a dynamic cohort study of the Japanese population: Yao City, Osaka Prefecture 147 
and Ikawa town, Akita Prefecture under a nationwide study. We recruited 507 148 
men aged 30–79 years one by one from January 2013 to May 2015 from 149 
participants who underwent annual cardiovascular risk surveys. Informed consent 150 
was obtained from community representatives based- on guidelines of the 151 
Council for International Organizations of Medical Science to perform an 152 
epidemiological study (14). The study protocol was approved by the Ethics 153 
Committee of the Osaka University. 154 
2.2. Measurement of FMD and CAP 155 
All participants had five minutes of rest in the seated posture, using a standard 156 
protocol (15). FMD was measured with high-resolution ultrasonography and 157 
forearm occlusive cuff by technicians. High-resolution ultrasound with a 10-158 
MHz linear array transducer was used to record longitudinal images of the right 159 
brachial artery. This transducer system can accurately capture and track the edge 160 
of target artery automatically once the probe is placed at the proper position. To 161 
standardize the position of the probe, we used a specially designed arm-rest and 162 
probe holder. The brachial artery diameter at baseline was measured by this 163 
system and then the brachial cuff was inflated to 50mm Hg above SBP for 5 164 
8 
minutes and deflated. Computer-assisted analysis software (UNEX Co. Ltd., 165 
Nagoya, Japan) was used to determine brachial artery diameter semi-166 
automatically, as previously described (16).  167 
The baseline longitudinal image of the artery was acquired for 30 seconds, after 168 
which the blood pressure cuff was inflated to 50 mmHg above systolic pressure 169 
for 5 minutes. FMD change (%FMD) was defined by the following 170 
formula: %FMD = ((maximal artery lumen diameter after cuff release-artery 171 
lumen diameter at baseline)/artery-lumen diameter at baseline) ×100, according 172 
to published guidelines for determining endothelial function (17). The coefficient 173 
of inter-observer variability for FMD measurements in our laboratory was 5.7 %, 174 
while that of intra-observer variability were 11.1% apart from 2 months and 175 
10.8% apart from 4 months. In previous studies, the coefficient of inter-observer 176 
variability for FMD measurement was 1.3% to 3.5% (18, 19), and that for intra-177 
observer variability was 15.6% apart from 48 hours and 18.3% apart from 3 178 
months (20). 179 
CAP was measured by technicians with an automated tonometer, HEM-9000AI 180 
(Omron, Healthcare Co., Kyoto, Japan). A previous clinical study used both 181 
HEM-9000AI and standard cardiac catheterization to examine the validity and 182 
reproducibility of CAP levels among 18 hypertension patients aged 47–78 years. 183 
The correlation coefficient was 0.95 (p < 0.001) between CAP levels by the two 184 
measurement systems, and 0.93 (p < 0.001) between the repeated CAP 185 
measurement by HEM-9000AI (6). 186 
9 
2.3. Measurement of cardiovascular risk factors 187 
We previously reported the protocols for measuring cardiovascular risk factors, 188 
such as blood pressure, serum lipids, body mass index (BMI), assessment of 189 
smoking and drinking habits, hypertension, and diabetes mellitus (10, 21, 22). 190 
Height in stocking feet and weight in light clothing were measured. Body mass 191 
index (BMI) (kg/m2) was calculated as weight in kilograms divided by height in 192 
square meters. Trained observers measured SBP and diastolic blood pressure 193 
(DBP) using a standard mercury sphygmomanometer on the right arm after 194 
participants had rested for 5 minutes (23). An interview was conducted to 195 
confirm information on habits, including drinking status, tobacco status, 196 
hypertension, and diabetes mellitus medication use. For drinking status, persons 197 
who reported consuming 0.3 gō (equivalent to 7 grams of ethanol) or more per 198 
week were regarded as current drinkers. Former drinkers were defined as 199 
abstainers for the previous 3 months or more. Trained interviewers also 200 
determined information on smoking status, use of antihypertensive agents, and 201 
medical history. Persons who smoked ≥1 cigarette per day were defined as 202 
current smokers.  203 
Blood samples were obtained on the same day as annual cardiovascular risk 204 
surveys from participants and the serum was separated immediately. 205 
Measurements of serum triglycerides were performed using a fluorometric 206 
method by an Autoanalyzer II (Technicon, Tarrytown, NY, U.S.A.), while total 207 
cholesterol and high density lipoprotein (HDL)-cholesterol measurements were 208 
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performed at the Osaka Medical Center for Health Science and Promotion lipid 209 
reference laboratory, a certified member of the US National Cholesterol 210 
Reference Method Laboratory Network (CRMLN), using enzymatic methods by 211 
an auto analyzer Olympus AU 2700 (24). Serum glucose measurements were 212 
performed by the hexokinase method, using the same instrument. Diabetes 213 
mellitus was defined as a fasting glucose level of ≥7.8 mmol/L, a non-fasting 214 
glucose level of ≥11.1 mmol/L, or use of medication for diabetes mellitus (25). 215 
Hypertension was defined as SBP ≥140 mmHg, DBP ≥90 mmHg, or use of 216 
antihypertensive medication (26). 217 
2.4. Statistical analysis 218 
We defined the low FMD as %FMD≤5.0 (lowest 30 percentile) based on 219 
previous reports that used the receiver-operating characteristic analysis (27, 28). 220 
Values of cardiovascular risk factors in subjects with %FMD≤5.0 and >5.0 are 221 
presented as mean ± standard deviation (SD) or proportions (%). The odd ratios 222 
(OR) with the respective 95% confidence intervals (CIs) of the low FMD were 223 
calculated according to tertiles of and 1-SD increment of CAP and SBP levels, by 224 
using logistic regression analysis, after adjusting for age in one model, and 225 
further adjustment for potential confounding factors including area of residence, 226 
heart rate, brachial artery baseline diameter, total serum cholesterol, serum 227 
triglycerides, history of diabetes mellitus, drinking status and smoking status. 228 
The analyses were repeated by stratifying antihypertensive medication use. 229 
All statistical analyses were performed with SAS version 9.4 software (SAS 230 
11 
Institute Inc., Cary, NC, USA). All probability values for statistical tests were 231 
two-tailed and values of p <0.05 were regarded as statistically significant. 232 
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3．Results 253 
The characteristics of 507 Japanese men are summarized in Table 1. The mean 254 
values of %FMD, age and BMI were 6.7, 54.1 years and 24.2kg/m2, respectively. 255 
Compared with participants in the group of %FMD≤5, those in the group 256 
of %FMD>5 had lower CAP, lower SBP levels and smaller brachial artery 257 
baseline diameter, and were less likely to be drinkers, diabetics and hypertensive. 258 
The ORs (95% CI) of the low FMD according to tertiles and 1-SD increment 259 
for CAP and SBP levels are given in Table 2. Among total 507 subjects, the 260 
multivariable ORs (95% CI) of the low FMD was 1.5(0.9–2.6) for the highest 261 
versus lowest tertiles of CAP, and 1.2(1.0-1.5) for 1-SD increment (16.3 mmHg) 262 
of CAP levels; while were 0.9(0.5–1.5) for the highest versus lowest tertiles of 263 
SBP, and 1.0(0.8-1.3) for 1-SD increment (13.9 mmHg) of SBP levels. 264 
When these associations were stratified by antihypertensive medication use, 265 
significant positive associations between CAP and the low FMD were observed 266 
primarily in subjects without antihypertensive medication use; the multivariable 267 
ORs (95%CI) of the low FMD was 2.4(1.2–4.8) for the lowest versus highest 268 
tertiles and 1.3(1.0-1.7) for 1-SD increment of CAP levels. There were no 269 
difference in the associations between SBP and low FMD in participants with 270 
and without the use of antihypertensive medication.  271 
 272 
 273 
 274 
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4．Discussion 275 
In the present community-based study of 507 Japanese men aged 30–79 years, 276 
CAP, but not brachial SBP, levels were correlated with the low FMD. The 277 
association between CAP and low FMD levels was evident for men who did not 278 
use antihypertensive medications.  279 
Low FMD is a surrogate marker of early atherosclerosis in Japanese (29), 280 
American (30), and European subjects (31). In a clinical study of 384 patients 281 
with suspected cardio metabolic disorders, %FMD was significantly reduced in 282 
patients with nonalcoholic fatty liver disease, diabetes, history of coronary heart 283 
disease, metabolic syndrome, and in those taking antihypertensive drugs (31). 284 
The Multi-Ethnic Study of Atherosclerosis for 2,936 men and women (mean age 285 
61 years) showed that a 1-SD (2.8%) increase in %FMD values was associated 286 
with lower risk of incident auricular fibrillation [Hazard ratio (HR) =0.84, 287 
95%CI=0.70, 0.99], suggesting that markers of endothelial dysfunction 288 
contributes to the pathogenesis of auricular fibrillation (30).  289 
To our knowledge our study is the first to show that CAP levels were associated 290 
more with reduced %FMD than SBP levels in men without use of 291 
antihypertensive medication. Lind L has reported that CAP measurement was not 292 
superior over traditional blood measurements regarding its relation to 293 
endothelium-dependent vasodilatation or FMD (32). However, that study was 294 
conducted only among elder participates over 70 years old. It was previously 295 
shown that the absolute difference between aortic and brachial systolic pressures 296 
14 
declined with age (<20y up to 69 years) and then the difference plateaued after 297 
ages≥70 years (33). Our study supports the previous finding from a clinical study 298 
of 201 type 2 diabetes patients that an ankle-brachial index, a surrogate marker of 299 
atherosclerosis, was more strongly correlated with CAP than SBP levels (CAP: 300 
r=0.162, p=0.04, SBP: r=0.083, p=0.30) (34). Compared with a 10 mmHg 301 
increment of SBP, the same increment of CAP was more strongly associated with 302 
mortality risk from cardiovascular disease in a cohort study of normotensive and 303 
untreated hypertensive Taiwanese; the multivariable HR (95% CI) of 304 
cardiovascular mortality was 1.34(1.10–1.49) for CAP and 0.96(0.79–1.16) for 305 
SBP (12).Our previous study found that CAP levels were associated with 306 
subclinical damage expressed by minor ST-T ECG abnormalities (8). 307 
Furthermore, a clinical study of 146 hypertensive patients reported that left 308 
ventricular mass change was more strongly correlated with CAP than SBP (35). 309 
These findings support CAP as a more sensitive marker for the loading 310 
conditions on the heart and coronary arteries than SBP.  311 
In the current study, the lack of association between CAP levels with %FMD 312 
among subjects with antihypertensive medication use may be due to the dilution 313 
of association after lowering CAP levels by various amounts. On the other hand, 314 
the lack of association between SBP levels and %FMD in total subjects 315 
regardless of antihypertensive medication use might probably due to the small 316 
number of severe high blood pressure patients (SBP≥160 mmHg, n=21). 317 
The strengths of the present study include the use of a noninvasive technique 318 
15 
for measuring CAP and FMD and the standardized measurements of other 319 
cardiovascular risk factors in community population-based samples (22).    320 
However, this study has several limitations as follows: first, details of 321 
antihypertensive drug treatment were not available. Antihypertensive drugs such 322 
as calcium channel antagonist, ACE-inhibitors and AT1-receptor antagonists can 323 
improve endothelial function (36). However, we could not investigate whether 324 
the lack of association between CAP levels and reduced %FMD in men with 325 
antihypertensive medication use might be attributable to the effects of those 326 
drugs or not. Second, reduced %FMD was the only indicator for endothelial 327 
dysfunction in the current study; no data were available for nitrate-induced 328 
vasodilatation. Last, our subjects were not recruited randomly, but they were 329 
selected consecutively, and thus generalizability of our findings is limited. We 330 
also were unable to include women in the current analysis because of very small 331 
sample size, and further investigation will be necessary. 332 
In conclusion, higher CAP levels were associated with low FMD for men 333 
without antihypertensive medication, but such an association was not found for 334 
SBP levels. 335 
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Table 1. Mean values ± standard deviations and proportions of cardiovascular risk 
factors among 507 Japanese men. 
  
Total number 
%FMD 
P for 
difference a ≤5 >5 
507 153 354 
Mean % flow-mediated dilation 6.7±0.1 3.7±0.1 6.3±0.1   
%FMD≤5, n 153       
Brachial artery baseline diameter, mm 4.5±0.6 4.7±0.6 4.4±0.5 <0.01 
Age, years 54.1±0.5 56.9±0.7 53.0±0.6 <0.0001 
Body mass index, kg/m2 24.2±0.2 24.3±0.3 24.2±0.2 0.6 
Central aortic pressure, mmHg 124.5±0.8 127.9±1.4 123.1±0.9 <0.01 
Systolic blood pressure, mmHg 129.2±0.7 132.1±1.3 127.9±0.9 0.05 
Diastolic blood pressure, mmHg 82.3±0.5 83.2±0.8 82.6±0.6 0.56 
Total cholesterol, mg/dL 202.2±1.5 200.2±2.7 203.0±1.7 0.47 
Triglycerides, mg/dL 135.9±4.7 141.0±8.4 133.7±5.7 0.58 
HDL-cholesterol, mg/dL 56.6±0.7 57.1±1.1 56.4±0.8 0.88 
Current drinkers, % 74 76 73 0.02 
Current smokers, % 33 37 31 0.31 
Diabetes mellitus, % 8 12 7 0.07 
Hypertension, % 35 45 31 <0.01 
Antihypertensive medication use, % 26 35 21 <0.01 
a Chi-square test was used for categorical variables; ANOVA was used for continuous variables. 
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Table 2. Age- and multivariable-adjusted odds ratio (95% CI) of low FMD according to tertiles of central aortic pressure and 
systolic blood pressure in Japanese men. 
 Tertiles of central systolic aortic pressure  (mmHg) OR per 1-SD 
increment b 
 Tertiles of brachial systolic blood pressure  (mmHg) OR per 1-SD 
increment b 
 T1 (Low) T2 T3 (High)  T1 (Low) T2 T3 (High) 
Total subjects, No. 169 173 165   165 171 171  
Range of pressure ≤115 116-130 ≥131   ≤122 123-135 ≥136  
Mean %FMD ± SD          
Age-adjusted %FMD 6.9±0.2 6.7±0.2 6.4±0.2   6.8±0.2 6.6±0.2 6.6±0.2  
Multivariable-adjusted %FMD a 6.8±0.2 6.8±0.2 6.4±0.2   6.6±0.2 6.6±0.2 6.7±0.2  
Low FMD, No. 41 51 61   44 53 56  
            Age-adjusted OR 1 1.1(0.7-1.8) 1.5(0.9-2.4) 1.2(1.0-1.4)  1 1.0(0.6-1.7) 1.0(0.6-1.7) 1.2(0.9-1.4) 
            Multivariable-adjusted OR a 1 1.1(0.6-1.9) 1.5(0.9-2.6) 1.2(1.0-1.5)  1 0.9(0.5-1.6) 0.9(0.5-1.5) 1.0(0.8-1.3) 
Subjects without antihypertensive medication use 142 124 111   145 127 105  
Range of pressure ≤113 114-128 ≥129   ≤118 119-132 ≥133  
Mean %FMD ± SD          
Age-adjusted %FMD ± SD 7.3±0.3 6.9±0.3 6.6±0.3   7.2±0.3 6.8±0.3 6.8±0.3  
Multivariable-adjusted %FMD ± SD a 7.1±0.3 7.0±0.3 6.6±0.3   7.1±0.3 6.8±0.3 6.9±0.3  
Low FMD, No 29 32 38   30 38 31  
          Age-adjusted OR 1 1.5(0.8-2.7) 2.0(1.1-3.7) 1.2(1.0-1.5)  1 1.3(0.7-2.3) 1.4(0.8-2.5) 1.1(0.9-1.4) 
          Multivariable-adjusted OR a 1 1.9(0.9-3.9) 2.4(1.2-4.8) 1.3(1.0-1.7)  1 1.2(0.7-2.3) 1.3(0.7-2.5) 1.1(0.8-1.4) 
Subjects using antihypertensive medication 27 49 54   20 44 66  
Range of pressure ≤123 124-137 ≥138   ≤128 129-140 ≥141  
Mean %FMD ± SD          
Age-adjusted %FMD ± SD  5.6±0.5 6.1±0.4 5.8±0.4   4.5±0.6 6.1±0.4 6.1±0.3  
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Multivariable-adjusted %FMD ± SD a 5.5±0.5 6.2±0.4 5.7±0.4   4.5±0.6 6.2±4 6.0±0.3  
Low FMD, No. 12 19 23   14 15 25  
Age-adjusted OR 1 1.2(0.5-2.8) 1.3(0.6-3.1) 1.1(0.8-1.5)  1 0.5(0.2-1.1) 0.8(0.3-1.8) 1.0(0.7-1.4) 
Multivariable-adjusted OR a 1 1.1(0.4-3.0) 1.4(0.5-3.8) 1.2(0.8-1.8)  1 0.5(0.2-1.4) 0.8(0.3-2.2) 0.9(0.5-1.4) 
1-SD for CAP= 16.3 mmHg, and 1-SD for SBP= 13.9 mmHg. 
a Adjusted for age, area of residence, heart rate, brachial artery baseline diameter, total serum cholesterol, serum triglycerides, history of diabetes mellitus, drinking 
status, and smoking status. 
b Calculated  by linear regression analysis. 
